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http://www.biomedcentral.com/1471-2180/13/217RESEARCH ARTICLE Open AccessSelective photoinactivation of Candida albicans in
the non-vertebrate host infection model Galleria
mellonella
José Chibebe Junior1,2,3†, Caetano P Sabino4,5†, Xiaojiang Tan6,2†, Juliana C Junqueira1*, Yan Wang2,7,
Beth B Fuchs2, Antonio OC Jorge1, George P Tegos4,8,9, Michael R Hamblin4,9,10 and Eleftherios Mylonakis2,11Abstract
Background: Candida spp. are recognized as a primary agent of severe fungal infection in immunocompromised
patients, and are the fourth most common cause of bloodstream infections. Our study explores treatment with
photodynamic therapy (PDT) as an innovative antimicrobial technology that employs a nontoxic dye, termed a
photosensitizer (PS), followed by irradiation with harmless visible light. After photoactivation, the PS produces either
singlet oxygen or other reactive oxygen species (ROS) that primarily react with the pathogen cell wall, promoting
permeabilization of the membrane and cell death. The emergence of antifungal-resistant Candida strains has
motivated the study of antimicrobial PDT (aPDT) as an alternative treatment of these infections. We employed the
invertebrate wax moth Galleria mellonella as an in vivo model to study the effects of aPDT against C. albicans
infection. The effects of aPDT combined with conventional antifungal drugs were also evaluated in G. mellonella.
Results: We verified that methylene blue-mediated aPDT prolonged the survival of C. albicans infected G. mellonella
larvae. The fungal burden of G. mellonella hemolymph was reduced after aPDT in infected larvae. A fluconazole-
resistant C. albicans strain was used to test the combination of aPDT and fluconazole. Administration of fluconazole
either before or after exposing the larvae to aPDT significantly prolonged the survival of the larvae compared to
either treatment alone.
Conclusions: G. mellonella is a useful in vivo model to evaluate aPDT as a treatment regimen for Candida infections.
The data suggests that combined aPDT and antifungal therapy could be an alternative approach to antifungal-
resistant Candida strains.
Keywords: Candida albicans, Photodynamic therapy, Galleria mellonellaBackground
Candida albicans and other Candida species commonly
colonize the epithelial surfaces of the human body [1].
One-half of humans have oral cavities colonized by Can-
dida species in a commensal relationship with the host
[2]. Although few healthy carriers develop clinical can-
didiasis, when the host becomes immunocompromised
due to cancer, HIV/AIDS, diabetes, major surgery, trans-
plantation of solid organs or hematopoietic stem cells,
these opportunistic pathogens can cause superficial* Correspondence: julianacjunqueira@hotmail.com
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distribution, and reproduction in any mediuminfections that may be cutaneous, subcutaneous or mu-
cosal. In progressive cases, the fungus can penetrate the
epithelial surface and be disseminated by the blood-
stream with serious consequences [1,3-7].
C. albicans is the most common species isolated from
superficial and systemic candidiasis and it is considered
the most pathogenic species of the Candida genus
[5,8-11]. In vitro investigations indicate that C. albicans
expresses higher levels of putative virulence factors com-
pared to other Candida species. It has been proposed
that several virulence factors are involved in the patho-
genicity of C. albicans, such as adhesion to host sur-
faces, hyphal formation and secretion of proteinases
[11]. In addition, C. albicans cells employ mechanismsCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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system, including an efficient oxidative stress response
[12,13]. When immunocompetent individuals are
infected by fungi, macrophages and neutrophils gener-
ate reactive oxygen species (ROS), such as superoxide
radicals and hydrogen peroxide that damage cellular
components of C. albicans, inclusive of proteins, lipids
and DNA. The production of ROS is an important
mechanism of host defense against fungal pathogens
[13], damaging cells enough to cause cell death of
phagocytosed fungal cells [12,14].
Treatment of fungal infections, especially invasive
ones, is considered difficult due to the limited availabil-
ity of antifungal drugs and by the emergence of drug-
resistant strains. The development of new antifungal
agents and new therapeutic approaches for fungal infec-
tions are therefore urgently needed [4,8,15]. Photo-
dynamic therapy (PDT) is an innovative antimicrobial
approach that combines a non-toxic dye or photosensi-
tizer (PS) with harmless visible light of the correct
wavelength. The activation of the PS by light results in
the production of ROS, such as singlet oxygen and hy-
droxyl radicals, that are toxic to cells [6,16]. PDT is a
highly selective modality because the PS uptake occurs
mainly in hyperproliferative cells and cell death is
spatially limited to regions where light of the appropri-
ate wavelength is applied. As microbial cells possess
very fast growth rates, much like that of malignant cells,
PDT has been widely used for microbial cell destruction
[17]. Several in vitro studies have shown that PDT can
be highly effective in the inactivation of C. albicans and
other Candida species. Therefore, antifungal PDT is a
subject of increasing interest especially against Candida
strains resistant to conventional antifungal agents [16].
Galleria mellonella (the greater wax moth) has been
successfully used to study pathogenesis and infection
by different fungal species, such as Candida albicans,
Cryptococcus neoformans, Fusarium oxysporum, Asper-
gillus flavus and Aspergillus fumigatus [18]. Recently,
our laboratory was the first to describe G. mellonella as
an alternative invertebrate model host to study anti-
microbial PDT alone or followed by conventional thera-
peutic antimicrobial treatments [19]. We demonstrated
that after infection by Enterococcus faecium, the use of
antimicrobial PDT prolonged larval survival. We have
also found that aPDT followed by administration of a
conventional antibiotic (vancomycin) was significantly
effective in prolonging larval survival even when
infected with a vancomycin-resistant E. faecium strain.
In this study, we go on to report the use of the inver-
tebrate model G. mellonella as a whole animal host for
the in vivo study of antifungal PDT, as well as the study
of combined therapy using PDT and a conventional an-
tifungal drug.Methods
Microbial strains and culture conditions
The C. albicans strains used in this study were Can14
and Can37. C. albicans Can14 is a wild-type strain
SC5314 [20] and C. albicans Can37 is a fluconazole re-
sistant clinical isolate from a patient with oropharyngeal
candidiasis [3]. C. albicans Can37 was identified by
growth on Hicrome Candida (Himedia, Munbai, India),
germ tube test, clamydospore formation on corn meal
agar, and API20C for sugar assimilation (BioMerieux,
Marcy Etoile, France). Susceptibility pattern to flucona-
zole was determined by the broth microdilution assay
according to the Clinical and Laboratory Standards In-
stitute (CLSI).
Strains were stored as frozen stocks with 30% glycerol
at −80°C and subcultured on YPD agar plates (1% yeast
extract, 2% peptone, and 2% dextrose) at 30°C. Strains
were routinely grown in YPD liquid medium at 30°C in
a shaking incubator.
Fungal inocula preparation
C. albicans cells were grown in YPD at 30°C overnight.
Cells were collected with centrifugation and washed
three times with PBS. Yeast cells were counted using a
hemocytometer. The cell number was confirmed by de-
termining colony-forming units per mL (CFU/mL) on
YPD plates.
Inoculation of G. mellonella with C. albicans strains
G. mellonella (Vanderhorst Wholesale, St. Marys, OH,
USA) in the final larval stage were stored in the dark
and used within 7 days from shipment. Sixteen randomly
chosen G. mellonella larvae with similar weight and size
(250-350 mg) were used per group in all assays. Two
control groups were included: one group was inoculated
with PBS to observe the killing due to physical trauma,
and the other received no injection as a control for gen-
eral viability.
A Hamilton syringe was used to inject 5 μL inoculum
aliquots into the hemocoel of each larvae via the last left
proleg containing 106 CFU/larvae of C. albicans cells
suspended in PBS. After injection, larvae were incu-
bated in plastic containers at 37°C and monitored for
survival daily.
Chemicals and photosensitizer
Methylene blue (MB, Sigma, St Louis, MO) was used at
a final working concentration of 1 mM. The dye was
dissolved in distilled and deionized filter sterilized water
(ddH2O). For each experiment, a new PS solution was
prepared daily. Fluconazole (Sigma-Aldrich, Steinheim,
Germany) was dissolved in ddH2O and injected in G.
mellonella at a concentration of 14 mg/Kg.
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The G. mellonella larvae were injected with 10 μL of a
1 mM solution of MB 90 min after the Candida infec-
tion and the PS was allowed to disperse for 30 min into
the insect body in the dark, prior to the light irradiation.
A broad-band non coherent light source (LumaCare,
Newport Beach, CA) was used for light delivery. This
device was fitted with a 660 ± 15 nm band-pass filter
probe that was employed to produce a uniform spot for
illumination. The optical power was measured using a
power meter (PM100D power/energy meter, Thorlabs,
Inc., Newton, NJ).
Antifungal administration
For the study of aPDT combined with conventional an-
tifungal drug, fluconazole (14 mg/kg) was injected im-
mediately before or after the exposure of larvae to light.
As a control, a group of the larvae received an injection
containing PBS, in lieu of fluconazole.
G. mellonella survival assays
After aPDT or combined treatment of aPDT with flucona-
zole, larvae were observed every 24 h, and considered dead
when they displayed no movement in response to touch.
Survival curves were plotted and statistical analysis was
performed by the Log-rank (Mantel-Cox) test using Graph
Pad Prism statistical software. A P value <0.05 was consid-
ered statistically significant. All experiments were repeated
at least twice, representative experiments are presented.
Persistence of C. albicans in the hemolymph of G.
mellonella
The number of fungal cells recovered from the hemolymph
of G. mellonella infected by C. albicans Can37 was mea-
sured immediately after larvae were exposed to aPDT and
to combined treatment (aPDT and fluconazole). Three sur-
viving larvae per group were bled by insertion of a lancet
into the hemocoel. Hemolymph from 3 larvae was pooled
into 1.5 ml Eppendorf tubes in a final volume of approxi-
mately 80 μL. Then, the hemolymph was serially diluted
and plated on Sabouraud dextrose agar supplemented with
chloramphenicol (100 mg/L). Plates were incubated aerob-
ically at 37°C for 24 h, and colonies were counted in each
pool (CFU/pool). The groups exposed to aPDT were com-
pared to the control groups by Student t test. Difference in
the number of CFUs were considered statistically signifi-
cant at P < 0.05. The experiments were repeated at least
twice and representative experiments are presented. Three
polls per group were performed in each experiment.
Results
We previously described the utility of the G. mellonella
model host to assess antibacterial PDT efficacy against
E. faecium [19]. In this study we explored the potential ofthis model using antifungal therapy against one of the
most common opportunistic fungal pathogens C. albicans.
Briefly, after 90 min of Candida infection, G. mellonella
larvae were treated with PDT mediated by MB and red
light according to the methods described.
As a first step in exploring the optimal dose–response
to MB mediated-PDT, we evaluated 10 groups of larvae
that were infected with the wild-type strain of C. albicans
(Can14) and received MB (1 mM) injection. We gradually
increased the light exposure time. More specifically, eight
groups were exposed to red light at different fluences (0.9,
1.8, 3.6, 5.4, 7.2, 10.8, 14.4 and 18 J/cm2, corresponding to
30, 60, 120, 180, 240, 360, 480 and 600 s of irradiation),
while two control groups received injection of PBS or MB
with no light exposure. After irradiation, the survival rate
of G. mellonella was assessed 24 h post C. albicans infec-
tion. The best survival rate was reached with the lowest
dose and 30 s of irradiation time (data not shown).
As a second step, a finer evaluation to establish the
optimum light dosimetry was performed. Eight further
groups were employed to analyze the photodynamic ef-
fects at 15, 30, 45, 60, 75, 90, 105 and 120 s of irradiation
(0.45, 0.9, 1.35, 1.8, 2.25, 2.7 and 3.6 J/cm2) and once again
0.9 J/cm2 (30 s of irradiation) provided the best survival
rate (Figure 1).
As a third step, a further comprehensive experimental
procedure was designed to assess the effects of aPDT, me-
diated by the optimum dose (1 mM MB and red light at
0.9 J/cm2), on host curve survival when infected by the
wild-type strain C. albicans Can14 and the fluconazole
resistant isolate C. albicans Can37. We observed that MB-
mediated aPDT, prolonged the larval survival when com-
pared to non-PDT treated larvae, however a statistically
significant difference between PDT and control groups
was observed only for C. albicans Can14 (Figure 2).
Since it was observed that fluconazole resistant strain
(Can37) showed reduced sensitivity to PDT, we evaluated
the number of CFU within the hemolymph to determine
if the fungal burden was reduced even if survival was not
significantly increased. We compared the hemolymph bur-
den of aPDT-treated larvae with non-treated larvae and a
significant reduction in the CFU number was observed
post-PDT treatment (Figure 3). These results confirmed
that aPDT was able to reduced fungal cell viability (0.2
Log) immediately upon light exposure, suggesting that
singlet oxygen and other ROS were produced, leading to
cell damage [21,22].
The reduced fungal burden indicates that the aPDT
treated cells are potentially damaged and thus the sur-
vival might be altered by the addition of another cell
membrane directed bombarding compound, a struc-
ture important for the maintenance of cell wall integ-
rity. Hence, we investigated the effects of combined
treatment of aPDT with fluconazole, a compound that
Figure 1 Dose–response 24 h after aPDT in G. mellonella infected by C. albicans Can14. Larvae were infected with 1x106 CFU/larva of C.
albicans Can14. The best survival rate was found when the fluence of 0.9 J/cm2 was applied.
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ponent of the cell membrane. This antifungal agent is used
extensively because of its low host toxicity to treat fungal
infections. One of the mechanisms that can be used by C.
albicans to develop resistance to fluconazole is related to
the overexpression of cell membrane multidrug efflux sys-
tems [23,24]. Based on the hypothesis that aPDT could
damage the cell membrane of C. albicans, producing in-
creased membrane permeability [25] and possibly damaging
efflux pumps, we used G. mellonella-C. albicans system to
assess the sequential combination of PDT with fluconazole.
G. mellonella were inoculated with 1.41 × 106 CFU/larva to
infect the larvae with the fluconazole-resistant C. albicans
strain (C. albicans Can37). Larvae treated only with PDT or
only with fluconazole did not show significantly prolonged
larval survival. The sequential combination with flucona-
zole, before or after PDT, significantly increased larvae sur-
vival in both assays (Figure 4). These results suggest that
aPDT increases the susceptibility of C. albicans Can37 to
fluconazole.
Discussion and conclusion
In this study we used the invertebrate model G. mellonella
for the in vivo study of antifungal PDT. We verified that
aPDT prolonged the survival of G. mellonella caterpillarsinfected by C. albicans and reduced the fungal burden in
the hemolymph of these animals. In addition, we used a
fluconazole-resistant C. albicans strain to test the combin-
ation of aPDT and fluconazole. The data presented here
demonstrated that aPDT increased the susceptibility of C.
albicans to fluconazole.
The increased numbers of fungal infections and the sub-
sequent need for high-cost and time-consuming develop-
ment of new antimicrobial strategies and anti-infectives
has emerged as a major problem among infectious dis-
eases researchers and clinicians [6,26]. Antimicrobial PDT
is one of the most promising alternative countermeasures
for cutaneous or mucosal infections, caused by either bac-
teria or fungi [6,26].
Antifungal PDT is an area of increasing interest, as re-
search is advancing in answering fundamental questions
regarding the photochemical and photophysical mecha-
nisms involved in photoinactivation; producing new,
potent and clinically compatible PS; and in understand-
ing the effect of key microbial phenotypic multidrug re-
sistance, virulence and pathogenesis determinants in
photoinactivation. The novel concept of developing the
non-vertebrate infection model in G. mellonella to ex-
plore the efficacy of antifungal PDT provides many
competitive advantages [6].
Figure 2 Killing of G. mellonella by C. albicans exposed to antimicrobial PDT. In the aPDT group, the larvae received the PS injection 90 min
after the infection with C. albicans. In order to allow a good dispersion of the PS into the insect body, we waited at least 30 additional min after
the PS injection prior to the light irradiation. A control group received PS without light exposure. Larvae were maintained at 37°C. a) C. albicans
Can14 wild-type strain SC5314, b) C. albicans Can37 clinical isolate from oropharyngeal candidiasis and fluconazole resistant.
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benefits when compared to mammalian animals: there
are no ethical or legal concerns, no need for specialized
feeding or housing facilities, the management of the ani-
mal is very easy and no anesthesia is needed, animals are
inexpensive, and the use of large sample numbers in the
same group are possible [27-30]. G. mellonella has been
used to study host-pathogen interactions as an alterna-
tive host model to small mammals such as mice and rats
[9,27-29,31-40].
Our laboratory pioneered the use of G. mellonella as a
suitable invertebrate model host to study aPDT against
Enterococcus faecium [19]. In the present study this ap-
proach to investigating aPDT was successfully expanded
to include fungal pathogens. The optimal dose–response
to MB mediated-PDT was evaluated and 0.9 J/cm2
showed the best survival of G. mellonella caterpillars, aswas found in the E. faecium study. The same limited
non-toxic dosage of aPDT to G. mellonella was applied
to treat larvae infected by strains of Candida albicans.
During the G. mellonella killing assays, groups infected by
C. albicans that received aPDT treatment demonstrated
prolonged survival when compared to groups that did not
received treatment. However a statistically significant differ-
ence between PDT and control groups was observed only
for C. albicans Can14 wild-type strain. When the infection
was induced by a fluconazole resistant strain (Can37), a sta-
tistically significant difference between these groups was not
observed. Despite the fact that PDT has been described as a
potent agent against both antimicrobial-resistant and sensi-
tive microorganisms [6] we observed that a fluconazole-
resistant C. albicans strain was less sensitive to aPDT.
This difference has also been described in an in vitro
study performed by Dovigo et al. [41]. These authors
Figure 3 Number of fungal cells in G. mellonella hemolymph
immediately post exposed to antimicrobial PDT treatment.
Larvae were infected with 1.41x106 CFU/larva of C. albicans Can37
and were maintained at 37°C. After 90 min post-infection, the PS
was injected. We waited an additional 30 min prior to light
irradiation. After light irradiation, the bacterial burden was measured
immediately. Fungal burden was quantified from pools of three
larvae hemolymph. aPDT exposed groups resulted in a significant
fungal burden reduction when compared to the control group that
was not exposed to light. Bars and error bars represent, respectively,
the mean and standard deviation of three pooled larvae per group.
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and C. glabrata showed reduced sensitivity to aPDT in
comparison with reference strains susceptible to flucona-
zole, suggesting that resistance mechanisms of microor-
ganisms to traditional antifungal drugs could reduce
PDT effectiveness. According to Prates et al. [23], the re-
sistance of Candida strains to fluconazole usually in-
volves overexpression of cell membrane multidrug efflux
systems belonging to the ATP-binding cassette (ABC) or
the major facilitator superfamily (MFS) classes of trans-
porters. The authors showed that the overexpression of
both systems reduced MB uptake by fungal cells, as well
as the killing effect of aPDT, suggesting that ABCs and
MFSs are involved in the efficiency of aPDT mediated
by MB and red light. In addition, Arana et al. [42] demon-
strated that subinhibitory concentrations of fluconazole in-
duced oxidative stress and a transcriptional adaptative
response that was able to generate protection of C. albicans
against subsequent challenges with oxidants. The mecha-
nisms of protection against oxidative stress of fluconazole
resistant C. albicans strain may have enhanced the resist-
ance of C. albicans to oxidative damage caused by PDT.
In this study, we also evaluated the effects of aPDT on
fungal cells in the hemolymph of G. mellonella larvae
infected by fluconazole resistant C. albicans (Can37). Al-
though this C. albicans strain had not shown a significant
increase in survival rate in G. mellonella, it was observed
that aPDT caused a reduction of the number of fungal cells
in the hemolymph (0.2 Log) with a statistically significantdifference between aPDT and control groups. In addition,
these data demonstrated that aPDT was able to reduce
fungal cell viability immediately upon light exposure,
suggesting that C. albicans cells were sensitive to aPDT,
by the lethal oxidative damage of the singlet oxygen path-
way, in the experimental candidiasis in the G. mellonella
model. At the moment, all the aPDT studies performed
in vivo were developed in vertebrate models of rats and
mice using fluences of light much higher than the dose
used in our work [43-45]. Using an oral candidiasis mice
model, Costa and colleagues [44] found a reduction of
0.73 Log in the fungal cells recovered after erythrosine-
and LED-mediated aPDT when a fluence of 14 J/cm2 was
applied. Dai et al. [45] also demonstrated that aPDT, with
the combination of methylene blue and red light (78 J/
cm2), reduced (0.77 Log of CFU) the fungal burden in skin
abrasion wounds in mice infected with C. albicans.
Patients with fungal infections are often treated with
azole antifungal drugs, however Candida resistance to
azoles has been detected in recent years. Several mecha-
nisms of resistance have been reported including the
overexpression of cell membrane multidrug efflux pumps
previously cited, an alteration in the chemical structure of
the demethylase enzyme, and the incorporation of alterna-
tive sterols to ergosterol within the cell membrane [23,24].
Giroldo et al. [25] suggested that MB-mediated aPDT
caused damage to the cell membrane of the C. albicans
cells. If the hypothesis that aPDT could affect the cell
membrane is valid, the sequential use of aPDT with flu-
conazole could have a dual action on treating the infec-
tion. Conventional antimicrobial therapy could have aPDT
as an adjunct or as an alternative [15]. The combination of
PDT with antimicrobials has been used with success when
compared to either isolated approach [19,26,46]. Kato
et al. [43] verified that after exposure to sublethal aPDT,
the minimal inhibitory concentration (MIC) of fluconazole
against C. albicans was reduced compared to non-aPDT
treated strains.
Of note, we observed that the G. mellonella larvae sur-
vival after infection by the fluconazole resistant C. albicans
strain, was prolonged when fluconazole was administered
before or after aPDT, in comparison to the use of flucona-
zole or PDT alone. We believe that due to the per-
meabilization of the fungal cell membrane by the sublethal
PDT dose, fungal cells become more susceptible to flucon-
azole action. In addition, it has been suggested that the use
of azoles can increase the oxidative stress promoted by
PDT by contributing to ROS formation themselves [26].
Arana et al. [42] demonstrated that fluconazole was able to
induce oxidative stress in C. albicans in a dose- and time-
dependent manner, suggesting that ROS play a role in the
mechanism of action of azoles. The exact mechanism in-
volved in increasing the survival of larvae infected by the
fluconazole resistant C. albicans strain and exposed to
Figure 4 Killing of G. mellonella larvae after infection by C. albicans Can37 fluconazole resistant. The larvae received an injection of
1.4x106CFU/larva and were maintained at 37°C. a) administration of fluconazole (14 mg/kg) or PBS (Control), b) antimicrobial PDT or only MB
(Control), c) administration of fluconazole followed by aPDT in a combined therapy or PBS (Control), d) administration of aPDT followed by
fluconazole in a combined therapy or PBS (Control), e) administration of aPDT or fluconazole + PDT, f) administration of aPDT or fluconazole +
PDT. There was no significant difference on larvae survival when treatment was done only by injecting of fluconazole (P = 0.584) or aPDT alone
(P = 0.102). The combined treatment by application of aPDT followed or before fluconazole injection resulted in significantly lower death rates
when compared to a control groups (P = 0.0010 to aPDT followed by fluconazole, and P = 0.0018 when aPDT was applied after fluconazole
injection). A significant difference in survival was observed for combined treatment compared to aPDT alone (P = 0.0062 for aPDT followed by
fluconazole, and P = 0.0068 when aPDT was applied after fluconazole injection).
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clarified. Thus, comprehensive experiments are needed to
better understand whether this process could be useful to
treat antimicrobial resistant fungal infections.
In summary, the results obtained in this study showed
that G. mellonella is a suitable model host to study the anti-
fungal PDT in vivo. It is known that the G. mellonella
model is not restricted to studies that examine aspects of
the pathogenesis of fungal infections or antimicrobial ther-
apies, but also can be used to the study of host defenses
against fungal pathogens [30]. The insect immune response
demonstrates a number of strong structural and functional
similarities to the innate immune response of mammals
and, in particular, insect haemocytes and mammalian neu-
trophils have been shown to phagocytose and kill patho-
gens in a similar manner [47]. Recent studies demonstrated
that PDT can stimulate host defense mechanisms. Tanaka
et al. [21] used a murine methicilin-resistant Staphylococcus
aureus (MRSA) arthritis model and verified that the
MB-mediated PDT exerted a therapeutic effect against a
bacterial infection via the attraction and accumulation of
neutrophils into the infected region. Neutrophils are among
the first cells recruited to the illuminated area and their
main function is to release enzymes for killing infectious
organisms and secrete cytokines and other chemicals that
promote inflammation [48]. In this study, the effects of
aPDT on the immune system of G. mellonella were not in-
vestigated. Therefore, future studies need to be developed
to understanding the action of aPDT and methylene blue in
the haemocyte density and in the expression of a variety of
antimicrobial peptides involved in immune responses of G.
mellonella.
The key conclusion is that the G. mellonela - C. albicans
system is a suitable model to study antifungal PDT and to
explore combinatorial aPDT-based treatments. Thus, this
invertebrate animal model host provides a novel approach
to assess the effects of in vivo PDT, alone or in combin-
ation with antifungal compounds, on fungal infections
without the difficulties of mammalian models.Authors’ contributions
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